Melanoma Institute Australia Clinical Trial Pipeline: 11 Active Trials, 1 Changes This Month

What changed in the last 30 days

1 trial changed in the last 30 days: 0 stopped, 0 with notable changes, 1 with a minor change only.

Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.

Phase 2

9

Not charted: 2 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

NCT ID	Title	Condition	Status	Updated
Phase 2
NCT03340129	Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)	Melanoma Stage Iv	Recruiting	2026-10-08
NCT06288191	Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma	Cutaneous Squamous Cell Carcinoma	Recruiting	2026-07-08
NCT06767306	Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic…	Melanoma Metastatic	Recruiting	2026-05-07
NCT06999980	Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)	Cutaneous Melanoma	Recruiting	2026-02-19
NCT06151236	Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma	Merkel Cell Carcinoma	Recruiting	2026-02-17
NCT02858921	Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage…	Melanoma	Active, Not Recruiting	2026-08-24
NCT04207086	A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III…	Melanoma Stage III	Active, Not Recruiting	2026-04-23
NCT05418972	A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical…	Stage II Melanoma	Active, Not Recruiting	2026-02-05
NCT02374242	Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases	Melanoma	Active, Not Recruiting	2025-12-10
Not applicable
NCT07049276	The Multicentre Selective Lymphadenectomy Trial - 3	Cutaneous Melanoma, Stage III	Recruiting	2026-06-29
Not specified
NCT06536257	Personalised Immunotherapy Platform	Melanoma	Recruiting	2026-10-07